PATH, ULTA and CAN are among pre market gainers

seekingalpha2023-12-01

Neximmune (NEXI) +338%. Jeffs Brands (JFBR) +64% Received Regulatory Approvals in Spain and The Netherlands to Commence Sales. ShiftPixy (PIXY) +26%. Altimmune (ALT) +38% pulls back from twice-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

聰明的人做多
2023-12-02
聰明的人做多
牛逼

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2388681230?lang=zh_CN&edition=full","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","is_english":true,"pubTime":"2023-12-01 21:31","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2388681230","market":"us","top_or_hot":-1,"title":"PATH, ULTA and CAN are among pre market gainers","media":"seekingalpha","content":"<div>\n<p>Neximmune  (NEXI) +338%.\nJeffs Brands  (JFBR) +64% Received Regulatory Approvals in Spain and The Netherlands to Commence Sales.\n\nShiftPixy  (PIXY) +26%.\nAltimmune (ALT) +38% pulls back from twice-...</p>\n\n<a href=\"https://seekingalpha.com/news/4042179-path-ulta-and-can-are-among-pre-market-gainers\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PATH, ULTA and CAN are among pre market gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPATH, ULTA and CAN are among pre market gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-01 21:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4042179-path-ulta-and-can-are-among-pre-market-gainers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neximmune  (NEXI) +338%.\nJeffs Brands  (JFBR) +64% Received Regulatory Approvals in Spain and The Netherlands to Commence Sales.\n\nShiftPixy  (PIXY) +26%.\nAltimmune (ALT) +38% pulls back from twice-...</p>\n\n<a href=\"https://seekingalpha.com/news/4042179-path-ulta-and-can-are-among-pre-market-gainers\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEXI","symbol_name":"NexImmune, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/4042179-path-ulta-and-can-are-among-pre-market-gainers","article_id":"2388681230","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2388681230","pubTimestamp":1701437499,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Jeffs Brands  +64%Received Regulatory Approvals in Spain and The Netherlands to Commence Sales.Altimmune  +38%pulls back from twice-daily regime of weight-loss drug candidate.Biora Therapeutics  +29%clears Biora to begin Phase 1 testing of ulcerative colitis treatment.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEXI":"NexImmune, Inc.","PATH":"UiPath","BK4134":"信息科技咨询与其它服务","BK4122":"互联网与直销零售","BK4551":"寇图资本持仓","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","ULTA":"Ulta美容","BK4561":"索罗斯持仓","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4097":"系统软件","JFBR":"Jeffs Brands","BK4505":"高瓴资本持仓","ESTC":"Elastic N.V.","BK4200":"专卖店","FEBO":"晖宝","BK4142":"酒店、度假村与豪华游轮","ALT":"Altimmune, Inc.","BK4170":"电脑硬件、储存设备及电脑周边","BK4565":"NFT概念","PD":"PagerDuty, Inc.","CMND":"Clearmind Medicine, Inc.","TAOP":"淘屏","BK4006":"钢铁","BK4539":"次新股","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4023":"应用软件","BK4187":"航天航空与国防","CAN":"嘉楠科技","SHCO":"SOHO HOUSE & CO INC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","PIXY":"Shiftpixy Inc.","IOT":"Samsara, Inc.","HLP":"宏力型钢","BK4159":"经销商","BK4007":"制药","BK4130":"人力资源与就业服务","GCT":"大健云仓","BK4196":"保健护理服务","BK4220":"综合零售","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU0823411888.USD":"法巴消费创新基金 Cap","BIOR":"Biora Therapeutics, Inc.","BK4588":"碎股","BK4526":"热门中概股"},"translate_title":"PATH、ULTA和CAN是盘前赢家","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEXI":1,"CAN":1,"CMND":1,"ESTC":1,"FEBO":1,"GCT":1,"HLP":1,"IOT":1,"JFBR":1,"BIOR":1,"PATH":1,"PD":1,"PIXY":1,"SASI":1,"SHCO":1,"TAOP":1,"ULTA":1,"ALT":1},"content_text":"Neximmune  (NEXI) +338%.\nJeffs Brands  (JFBR) +64% Received Regulatory Approvals in Spain and The Netherlands to Commence Sales.\n\nShiftPixy  (PIXY) +26%.\nAltimmune (ALT) +38% pulls back from twice-daily regime of weight-loss drug candidate.\n\nBiora Therapeutics  (BIOR) +29% clears Biora to begin Phase 1 testing of ulcerative colitis treatment.\n\nSigma Additive Solutions  (SASI) +31%.\nClearmind Medicine  (CMND) +22%.\nElastic (ESTC) +18% Q2 earnings call reease\n\nFenbo Holdings Limited (FEBO) +17%.\nUiPath (PATH) +15%.\nSamsara (IOT) +13%.\nUlta Beauty  (ULTA) +11%.\nGigaCloud Technology  (GCT) +9% Q3 earnings call release\n\nCanaan  (CAN) +3%.\nPagerduty  (PD) +6% Q3 earnings call release\n\nTaoping  (TAOP) +6%.\nHongli Group (HLP) +6%.\nSoho House  (SHCO) +5%.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":247436374540296,"gmtCreate":1701447059883,"gmtModify":1701447303177,"author":{"id":"3476472488695615","authorId":"3476472488695615","name":"聰明的人做多","avatar":"https://static.tigerbbs.com/cb283203da58d2b01218c21d403896c0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3476472488695615","authorIdStr":"3476472488695615"},"htmlText":"牛逼","listText":"牛逼","text":"牛逼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/247436374540296","repostId":2388681230,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2388681230"}